QNCX Company Profile and Key Details

Quince Therapeutics, Inc. (NASDAQ:QNCX) closed at $3.65 USD, gaining $0.08 (2.38%) from the previous close of $3.57. The stock is currently mid-range between its 52-week high and low $0.72 and $4.55. With a market capitalization of about $203.52 million, Quince Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.04). Key stats such as the average daily volume over the past year has been around 671.05 thousand shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Quince Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dirk Thye, the company employs approximately 36 people and listed since May 09, 2019. Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases.

Quince Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.20. This means the shares are trading below this model’s fair value.

Quince Therapeutics, Inc. generated EPS of -$1.22 over the past year. Five-year average earnings growth is 7.53%. Wall Street analysts project EPS growth of 27.83% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $4.00. The high target offers 236.13% upside. The low target suggests 12.04% downside. The mean target is $6.67. This offers 86.83% upside. Quince Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 24.57%. The prior quarter beat by 21.43%. Over the last six quarters, Apple has recorded several small beats. These include -25.0% in April 01, 2024.

Quince Therapeutics, Inc. has 53.71 million shares outstanding. The public float is 44.78 million shares, elevated short interest at 1.87% of float. This equals 894.88 thousand shares. The short ratio is 4.61 days. Institutional investors hold 25.99% of the float. Insiders own 11.12%. EPIQ Capital Group, LLC holds 2.86 million shares, Lamond David has 2.35 million shares and Thye Dirk has 843.94 thousand shares.

Short-term trend indicators are bearishly aligned (SMA20 0.99%, SMA50 44.1%, SMA200 111.48%). The stock’s 14-day RSI is 57.53 (neutral), while the ATR of 0.36 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.54% below its high and over 395.63% above its low. Average 10-day trading volume of 925.12 thousand shares is slightly above the 3-month average of 619.17 thousand, indicating heightened recent market interest.

Our AI price prediction model suggests that Quince Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 26.05%, with price expected at $4.50 by January 02, 2026, within a range of $4.06 to $4.94 3-Month Outlook: Projected rise of 133.61%, reaching $8.34 by March 19, 2026, with a range of $8.17 to $8.62. 1-Year Outlook: Projected gain of 709.52%, with price at $28.90 by December 18, 2026, within a range of $32.35 to $32.82.

Quince Therapeutics, Inc. (NASDAQ:QNCX) shares are up 90.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Quince Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.4. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.21, suggesting 101.96% upside. Our AI forecast model points to short-term strength (26.05% over two weeks), a medium-term rise (133.61% over three months), and a longer-term gain (709.52% over one year), with expected trading ranges indicating moderate volatility.

Quince Therapeutics, Inc. trades at a P/E ratio of -3.4, slightly below the S&P 500 average, with a price-to-sales ratio of 1183.23 and a price-to-book ratio of 14.2 reflecting a rich premium to book value. The P/FCF stands at -6.64, also below market averages. Compared to sector medians, Quince Therapeutics, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.